Skip to main navigation

Search for:

Search

Rubius Therapeutics

About Us
Our Science
Our Pipeline
Investors & Media
Careers
Contact

Menu Search

Press Releases

Year

April 12, 2021

Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers

April 9, 2021

Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting

March 16, 2021

Rubius Therapeutics Prices Upsized Public Offering of Common Stock

March 15, 2021

Rubius Therapeutics Announces Proposed Public Offering of Common Stock

March 15, 2021

Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

March 12, 2021

Rubius Therapeutics Announces Webcast to Review Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors

March 10, 2021

Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting

February 23, 2021

Rubius Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

February 18, 2021

Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

February 9, 2021

Rubius Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Print Page

RSS Feeds

Share Page

Email Alerts

Contact Us

399 Binney St, Suite 300
Cambridge, MA 02139 617-679-9600

Share

LinkedIn Twitter

Home
About Us
Our Science
Our Pipeline
Investors
Careers
Sitemap
Terms of Use
Privacy Policy

© Rubius Therapeutics, Inc. 2021. All Rights Reserved. RUBIUS and RED PLATFORM are registered trademarks of Rubius Therapeutics, Inc. RUBIUS THERAPEUTICS, RED CELL THERAPEUTICS and RCT are trademarks of Rubius Therapeutics, Inc. All other trademarks referenced herein are the properties of their respective owners.

Facebook
Twitter
LinkedIn